Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Inclusion Criteria: Subjects with Non-Erosive Gastroesophageal Reflux Disease identifying their main symptom as heartburn. History of episodes of heartburn for 6 months or longer prior to screening. History of episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the electronic diary. Exclusion Criteria: Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study· Use of antacids (except for study supplied Gelusil®). Use of drugs with significant anticholinergic effects. Need for continuous anticoagulant (blood thinner) therapy. Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus. History of dilatation of esophageal strictures, other than a Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter). Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition. History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer. Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the screening endoscopy. Erosive Esophagitis seen on endoscopy during study screening. Co-existing diseases affecting the esophagus. Abnormal laboratory values that suggest significant clinical disease. Known acquired immunodeficiency syndrome (AIDS) Females pregnant or lactating. History of Alcohol abuse. History of Cancer within 3 years prior to screening. Chronic (>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.